Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended December 31, 2024. Due to the €2.6 million refinancing operation (announced in the press release dated March 26, 2025), the Company had to focus its efforts on the related discussions…
Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle mass, which can compromise patients’…
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025. Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th…
Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Biophytis announces today the settlement and delivery of its private placement in the amount of €2,599,979.72 (including the issuance premium), carried out through the issuance,…
Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at €0,25 per pre-funded unit; Gross…
Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity 96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility. New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal model. Biophytis announces new preclinical…
Biophytis revolutionizes sarcopenia Biophytis is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the key reference journal for research on sarcopenia. Key BIO101 Attributes from the SARA INT Trail include: Promising Efficacy: BIO101 350mg bid demonstrates a clinically meaningful…
Biophytis announces its participation to the BIO-Europe Spring 2025 in Milan Biophytis is pleased to announce its participation in BIO-Europe Spring 2025, taking place in Milan, Italy, from march 17 to 19, 2025. Edouard Bieth, our Chief Business Officer, will take part in numerous meetings throughout the conference. As one of the most innovative biotechnology…
Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) Biophytis announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse. The International Conference on Frailty and Sarcopenia Research (ICFSR) is a leading annual…
Biophytis unveils its outlook strategies for 2025 Biophytis today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development program for the treatment of obesity, Strategic licensing agreement signed with…